RECRUITING

A Study to Determine Number of Patients Who Develop High Ammonia Levels After Receiving Recombinant Erwinia Asparaginase

Description

This study evaluates the incidence of symptomatic hyperammonemia (high ammonia levels) in patients being treated with recombinant Erwinia asparaginase.

Conditions

Hematopoietic and Lymphatic System NeoplasmAcute Lymphobkastic Leukemia
Talk to us

Related Conditions:

Hematopoietic and Lymphatic System NeoplasmAcute Lymphobkastic Leukemia

Study Overview

On this page

Study Details

Study overview

This study evaluates the incidence of symptomatic hyperammonemia (high ammonia levels) in patients being treated with recombinant Erwinia asparaginase.

A Pilot Study to Establish Incidence and Characteristics of Patients At Risk for Symptomatic Hyperammonemia Secondary to Recombinant Erwinia Asparaginase

A Study to Determine Number of Patients Who Develop High Ammonia Levels After Receiving Recombinant Erwinia Asparaginase

Condition
Hematopoietic and Lymphatic System Neoplasm
Intervention / Treatment

-

Contacts and Locations

Rochester

Mayo Clinic in Rochester, Rochester, Minnesota, United States, 55905

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Followed by pediatric hematology/oncology
  • * Receiving recombinant Erwinia asparaginase for treatment of malignancy
  • * Patients \< 1 year of age
  • * Patients who have previously received recombinant Erwinia asparaginase within the past two weeks

Ages Eligible for Study

1 Year to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Mayo Clinic,

Catherine E. Martin, PharmD, RPh, PRINCIPAL_INVESTIGATOR, Mayo Clinic in Rochester

Study Record Dates

2025-12-01